Navigation Links
Nobelist discovers antidepressant protein in mouse brain

A protein that seems to be pivotal in lifting depression has been discovered by a Nobel Laureate researcher funded by the National Institutes of Health's National Institute of Mental Health (NIMH).

"Mice deficient in this protein, called p11, display depression-like behaviors, while those with sufficient amounts behave as if they have been treated with antidepressants," explained Paul Greengard, Ph.D., a Rockefeller University neuroscientist who received the 2000 Nobel Prize in Physiology or Medicine for discoveries about the workings of such neuronal signaling systems. He and his colleagues found that p11 appears to help regulate signaling of the brain messenger chemical serotonin, a key target of antidepressants, which has been implicated in psychiatric illnesses such as depression and anxiety disorders. They report on their findings in the January 6, 2005 issue of Science.

Brain cells communicate with each other by secreting messengers, such as serotonin, which bind to receptors located on the surface of receiving cells. Serotonin selective reuptake inhibitors (SSRIs), medications commonly prescribed for anxiety and depression, compensate for reduction in serotonin signaling by boosting levels and binding of serotonin to receptors. Previous studies have suggested that serotonin receptors are essential in regulating moods and in mediating the effects of SSRIs, but given the complexity of the serotonin system, exactly how these receptors work remains a mystery.

To explore how a particular serotonin receptor (5-HT1B) functions, Greengard and colleagues conducted tests to find out what proteins these receptors interact with in brain cells. They found that 5-HT1B interacts with p11, and according to Greengard, p11 plays a role in the recruitment of receptors to the cell surface where they are more functional.

This finding led the researchers to suspect that p11 levels might be directly involved in the development of depression, anxie
'"/>

Source:NIH/National Institute of Mental Health


Page: 1 2 3

Related biology news :

1. UCSD team discovers specialized, rare heart stem cells in newborns
2. University of Nevada, Reno research team discovers hormone that causes malaria mosquito to urinate
3. MIT chemist discovers secret behind natures medicines
4. Mayo Clinic collaboration discovers protein amplifies DNA injury signals
5. Expedition discovers marine treasures
6. Team discovers possible universal strategy to combat addiction
7. Joslin discovers signs of residual islet cell function in people with long-term type 1 diabetes
8. Contrary to common wisdom, scientist discovers some mammals can smell objects under water
9. U of S Vaccine and Infectious Disease Organization team discovers key step in flu virus replication
10. LSU professor discovers new species
11. Mayo discovers protein as potential tactic to prevent tumors

Post Your Comments:
(Date:11/23/2009)...ciated strain of the deadly superbug MRSAan infect...bioticsposes a far greater health threat than prev... according to a study in the December issue of Em...s easily picked up in fitness centers, schools, an...l burden of MRSA within hospitals, the report foun...
(Date:11/23/2009)...gests that a common oral bacterium may exacerbate ... et al, "Unique Lipids from a Common Human Bacteri...f Enhancing Autoimmunity," appears in the December.... , Multiple sclerosis (MS), a disease where the...affects nearly 1 in 700 people in the United State...
(Date:11/23/2009)... University of Alabama at Birmingham (UAB) researc...ing medical conditions (co-morbidity) do not expla...mericans compared to Caucasians who also have colo... Cancer , a journal of the American Cancer Societ... co-morbidity are independent predictors of poor s...
Breaking Biology News(10 mins):New study finds MRSA on the rise in hospital outpatients 2Factors from common human bacteria may trigger multiple sclerosis 2Racial disparity in colon cancer survival not easily explained, UAB researchers say 2VIASPACE Pursuing Renewable Energy Business in Asia 13353 1VIASPACE Pursuing Renewable Energy Business in Asia 13353 2VIASPACE Pursuing Renewable Energy Business in Asia 13353 3Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 1Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 2Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 3Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 4Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 5Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 6Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 1Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 2Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 3Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 4Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 5Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 6Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 7Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 8Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 9Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 10Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 11Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 12Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 13Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 14Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 15Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 16Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 17Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 18Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 19Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 20Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 21Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 22Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 23
...veling the complex mechanisms in the brain that re...etites are controlled by systems very similar to t...type of neuron that is essential for feeding behav... and undergo rapid weight loss. , Remarkably, th...only influenced eating behavior when they were rem...
...des insight into genetic basis of human diseaseHig...lds a map of genetic variation which can give clue...he current technologies collect genotypes, or info...t many scientists believe that drilling down to th... of each chromosome -- so-called haplotypes -- wil...
...he last ice age are the likely culprits in the ext...rican great mammals such as mammoths, mastodons an...da researcher. , Determining whether the first arr...inent at the end of the last Ice Age was responsib...d scientists because both events occurred at the s...
Other Biology News:An essential regulator of body weight revealed 2An essential regulator of body weight revealed 3An essential regulator of body weight revealed 4California computer scientists double volume of data in NIH biotech repository 2California computer scientists double volume of data in NIH biotech repository 3California computer scientists double volume of data in NIH biotech repository 4Study shows big game hunters, not climate change, killed off sloths 2Study shows big game hunters, not climate change, killed off sloths 3
(Date:11/24/2009)...dBLENHEIM,Ontario,Nov.24/PRNewswire-FirstCall/--Do...ssetsofHylandSeeds,adivisionofThompsonsLimitedofBl...expandDowAgroSciences,currentseedsbusinessasthecom... 2010 andDowAgroSciencesHerbicideTolerantTraitTec...dinthenearfuture. ,, "Thisacquisitionbringstoge...
(Date:11/24/2009)...Nov.24/PRNewswire-Asia/--NODPharmaceuticalsInc.ann...wedthepatentapplicationfor,itsnano-particleoraldel...yefficientapproachtoincorporatepeptidesor,proteins...ofdrugs,otherwiseadministeredasinjections.NODtechn...acromoleculardrugssuchasinsulin,interferon,growth...
(Date:11/24/2009)...ficacyendpointhasbeenmetforpatientswithadvanced-st...Y,Nov.24/PRNewswire-FirstCall/-AEternaZentarisInc....armaceuticalcompanyfocusedonendocrinetherapyandonc...2studywithitstargetedcytotoxicpeptideconjugate,AEZ...rrentendometrialcancer.Inapersonalizedhealthcareap...
(Date:11/24/2009)...ly,November24/PRNewswire/--HealthRoboticstodayanno...groupofselected,investors.ThisrecentlyformedToront...csCanada,Inc.andwillmarket,install,andsupport,Heal...sthe,revolutionaryproductofferingsi.v.STATION(TM),...illalsoprovideassistanceonan"asneeded,basis"toitss...
Breaking Biology Technology:Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2
...ONDON, Aug. 27 Following the successful acquisiti...ry, Chiltern, a leading,contract research organiza... its two early Phase units into a single operation... Phase is providing high quality early phase servi...ll established units in Slough,(just outside of Lo...
...AN DIEGO and INDIANAPOLIS, Aug. 26 Amylin,Pharmac...Company (NYSE: LLY ),in a conference call today p...ng the August 18, 2008 U.S. Food and Drug Administ... (exenatide) injection referencing,pancreatitis. T...referenced,in the alert, as well as others, and pr...
...otes Secured by Royalties on U.S. Sales of SANCTUR...26 Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV )...ement to institutional investors of $105.0 million...e secured by royalties to be,paid from sales in th...,(trospium chloride). SANCTURA and SANCTURA XR are...
Other Biology Technology:Chiltern Early Phase: Fully Integrated and Business Ready 2Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 2Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 3Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 4Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 5Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 6Indevus Announces Private Placement of $105 Million of Non-Recourse Notes 2Indevus Announces Private Placement of $105 Million of Non-Recourse Notes 3Indevus Announces Private Placement of $105 Million of Non-Recourse Notes 4
Rabbit Anti-Schizosaccharomyces pombe SpUlp2 Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-Human STX18 Polyclonal Antibody, Unconjugated from ABR-Affinity BioReagents
Anti-Human sRANKL Polyclonal Antibody, Biotin Conjugated from Cell Sciences
Mouse Anti-CD42d Monoclonal Antibody, Unconjugated, Clone CLB-SW16 (formerly 708) from Abcam
Biology Products: